Interferon alpha-2b treatment for exophytic nasal papillomas and human papillomavirus infection.

OBJECTIVES: Exophytic Sinonasal Papilloma (ESP) is a benign tumor of the sinonasal tract. Complete surgical excision by endoscopic surgery is the treatment of choice. However, a high recurrence rate (36% at 5-year follow-up) is associated with this method, which may indicate the presence of microorganisms such as Human Papillomavirus (HPV). It is important to note that the standard treatment for ESP does not include antiviral drugs. In our study, we are testing the effectiveness of an interferon-containing drug in reducing recurrence and postoperative reactions in patients with ESP. METHODS: We included 78 patients aged 23-83 years with a confirmed diagnosis of ESP by rhinoscopy and nasal endoscopy and a positive PCR test for HPV in nasal scrapings. To compare the results, we divided the patients into main and control groups. The main group received recombinant human interferon after surgery, while the control group did not receive the drug. We performed a statistical analysis to compare the proportion of patients without reactive manifestations at different stages of the postoperative period, as well as to compare the proportion of patients with recurrent ESP at certain stages of observation. RESULTS: The introduction of recombinant human interferon accelerated the resolution of postoperative reactions and promoted the healing of the nasal mucosa after surgical removal of the ESP. We also found a statistically significant association between treatment with recombinant interferon and a reduction in the recurrence rate of ESP. CONCLUSION: According to the results of the study, it was found that in the main group of patients who received rhIFN-α2b (recombinant human Interferon alpha 2b) in the postoperative period, the frequency of relapses of ESP and the time of postoperative recovery were significantly lower than in patients in the control group who did not take the drug. LEVEL OF EVIDENCE: Cohort Study.

Success in the use of oral propranolol in the treatment of infantile hemangioma in nasal tip - Report of two cases

Abstract Infantile hemangioma is the most common pediatric vascular tumor, with the following risk factors: low birth weight, prematurity, white skin, female gender, multiparity and advanced maternal age. The use of oral and topical beta-blockers, although recent, has emerged as the first line of treatment, with superior safety and efficacy to previously used therapies, such as corticosteroids and surgeries. This report describes two cases of nasal tip infantile hemangioma, treated with oral propranolol. Both presented excellent therapeutic responses.

Success in the use of oral propranolol in the treatment of infantile hemangioma in nasal tip - Report of two cases.

Infantile hemangioma is the most common pediatric vascular tumor, with the following risk factors: low birth weight, prematurity, white skin, female gender, multiparity and advanced maternal age. The use of oral and topical beta-blockers, although recent, has emerged as the first line of treatment, with superior safety and efficacy to previously used therapies, such as corticosteroids and surgeries. This report describes two cases of nasal tip infantile hemangioma, treated with oral propranolol. Both presented excellent therapeutic responses.

Multifocal primary cutaneous extranodal NK/T lymphoma nasal type.

Nasal type extranodal NK/T-cell lymphoma is a distinct entity according to the World Health Organization classification. Although 60% to 90% of patients with this disease present with a destructive mass in the midline facial tissues, it may also primarily or secondarily involve extranasal sites, like the skin. We report the case of a 77-year-old patient that came to our department with erythematous plaques of the right leg and eczematous lesions of the trunk. These lesions were biopsied and the patient was diagnosed with extranodal NK/T-cell lymphoma, nasal type. He was treated with multi-agent systemic chemotherapy but died 5 months after diagnosis. This case highlights the rarity and variability of cutaneous features of this disease and its aggressive course and poor prognosis.

Multifocal primary cutaneous extranodal NK/T lymphoma nasal type

Abstract Nasal type extranodal NK/T-cell lymphoma is a distinct entity according to the World Health Organization classification. Although 60% to 90% of patients with this disease present with a destructive mass in the midline facial tissues, it may also primarily or secondarily involve extranasal sites, like the skin. We report the case of a 77-year-old patient that came to our department with erythematous plaques of the right leg and eczematous lesions of the trunk. These lesions were biopsied and the patient was diagnosed with extranodal NK/T-cell lymphoma, nasal type. He was treated with multi-agent systemic chemotherapy but died 5 months after diagnosis. This case highlights the rarity and variability of cutaneous features of this disease and its aggressive course and poor prognosis.

Treatment of two cats with advanced nasal lymphoma with orthovoltage radiation therapy and systemic chemotherapy

Background: Feline nasal lymphoma is generally a localized and radiosensitive tumor. Treatment options include radiation therapy, chemotherapy, or a combination of both treatments. Chemotherapy alone is generally not effective, leading to median survival times of 98 to 358 days, while RT alone or a combination of RT and chemotherapy lead to median survivals of 19 months and 955 days, respectively. Orthovoltage radiation therapy, the only radiation available in Brasil, has the disadvantage of being superficial, treating only tumors of 2 cm or less and causing marked skin side effects. The objective of this paper is to report two cases of advanced feline nasal lymphoma, with cribriform plate destruction and central nervous system invasion, successfully treated with orthovoltage radiation therapy and systemic chemotherapy. Case: Two female mixed breed cats were presented with nasal discharge, sneezing and facial deformity. The second cat also had neurologic signalment. Definitive diagnosis in histopathology was lymphoma. Computed tomography revealed advanced disease in both cases, with intranasal mass, bone lysis, invasion of orbital space and central nervous system. Both cats were treated with radiation therapy combined with chemotherapy. The first case received radiation therapy for gross disease (12 daily fractions of 300 cGy, five times per week) and CCNU/prednisolone [...](AU)

Treatment of two cats with advanced nasal lymphoma with orthovoltage radiation therapy and systemic chemotherapy

Background: Feline nasal lymphoma is generally a localized and radiosensitive tumor. Treatment options include radiation therapy, chemotherapy, or a combination of both treatments. Chemotherapy alone is generally not effective, leading to median survival times of 98 to 358 days, while RT alone or a combination of RT and chemotherapy lead to median survivals of 19 months and 955 days, respectively. Orthovoltage radiation therapy, the only radiation available in Brasil, has the disadvantage of being superficial, treating only tumors of 2 cm or less and causing marked skin side effects. The objective of this paper is to report two cases of advanced feline nasal lymphoma, with cribriform plate destruction and central nervous system invasion, successfully treated with orthovoltage radiation therapy and systemic chemotherapy. Case: Two female mixed breed cats were presented with nasal discharge, sneezing and facial deformity. The second cat also had neurologic signalment. Definitive diagnosis in histopathology was lymphoma. Computed tomography revealed advanced disease in both cases, with intranasal mass, bone lysis, invasion of orbital space and central nervous system. Both cats were treated with radiation therapy combined with chemotherapy. The first case received radiation therapy for gross disease (12 daily fractions of 300 cGy, five times per week) and CCNU/prednisolone [...]

CMED in the treatment of nasal natural killer cell lymphoma with distant metastases.

INTRODUCTION: Nasal natural killer (NK) cell lymphoma that showed distant metastases generally showed an poor prognosis. We described a group of patients with these atypical presentation and that were treated with an intensive, short chemotherapy/radiotherapy regimen. METHODS: Sixty-one patients fulfilled the criteria for NK cell lymphoma with distant metastases and all have very poor prognostic factors: high clinical risk, multiple extranodal presentation and bulky disease (tumor mass >10 cm). They were treated with CMED (cyclophosphamide 2000 mg/m(2), iv, day 1, methotrexate 400 mg/m(2), iv, day 1(with leucovorin rescue), etoposide 400 mg/m(2) twice and dexametasone 40 mg daily for 4 days). If complete response (CR) was observed, they were received adjuvant radiotherapy (50 Gy) to nasal region. Patients with failure were treated with different salvage treatments. RESULTS: Forty nine patients achieved CR and 12 were considered failure, all patients that were failure and nine that relapse die secondary to tumor progression. Median follow-up were 46 months (range 34-68 months). Median has not been observed in relapse-free survival (RFS) and overall survival (OS). Actuarial curves at 5 years showed that RFS was 81% and OS was 65%. Treatment was well tolerated. CONCLUSIONS: Nasal NK cell lymphoma with distant metastases is considered an rare clinical entity, probably is under diagnosis because it has been included as stage III and IV in previous reports, that showed an very poor RFS and OS. The treatment herein report could achieve good response and outcome, but it is evident that more specific and aggressive therapy is necessary in these setting of patients.

Cordoma nasal: presentación de un caso / Nasal cordome: the presentation of a case

Se presenta el caso de un paciente, mestizo masculino de 39 años de edad, que es visto en consulta por sangramiento nasal. Al examen físico se detecta masa tumoral que ocupa la fosa nasal izquierda. Se toma muestra para biopsia informándose la presencia de un cordoma de localización nasal. Se realizan complementarios correspondientes y se indica terapéutica oportuna...

Chemotherapy for cranial base tumors.

The tumors I will discuss in this chapter on chemotherapy will be ethesioneuroblastoma, salivary gland tumors, chordoma and nasopharyngeal carcinoma. Due basically to the rarity of these lesions, with the exception of nasopharyngeal carcinoma, there have been no multi-institutional studies of chemotherapy use reported in the literature. As a result, there is no clear-cut consensus on the standard of care as it relates to chemotherapy for these tumors. As with most authors who have previously reviewed these tumor types, I believe it is important for us to propose protocols of therapy and test these in arenas where we can accumulate enough patients for meaningful results. In this way, we can test the apparently active agents and combinations in relapsed or extensive disease. We might also begin to explore concurrent therapy (i.e., concurrent radiation and chemotherapy after the surgical procedure, for example).